Search research articles
Contact Us
Filters
Showing results (71-80 of 81) with videos related to
Page
of 9
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
August 30, 2016
The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic
Suzette Delaloge, Julia Bonastre, Isabelle Borget, et al.
Annales De Pathologie
|
July 2, 2019
[GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting]
Aurélie Maran-Gonzalez, Camille Franchet, Raphaëlle Duprez-Paumier, et al.
BMC Cancer
|
July 24, 2013
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
Jocelyne Jacquemier, Frédérique Spyratos, Benjamin Esterni, et al.
Annales De Pathologie
|
August 16, 2021
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France]
Camille Franchet, Lounes Djerroudi, Aurélie Maran-Gonzalez, et al.
Annales De Pathologie
|
December 3, 2014
[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France]
Gaëtan MacGrogan, Marie-Christine Mathieu, Bruno Poulet, et al.
Annales De Pathologie
|
December 3, 2014
[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]
Frédérique Penault-Llorca, Anne Vincent-Salomon, Gaëtan MacGrogan, et al.
Oncotarget
|
October 21, 2016
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients
David G Cox, Elsa Curtit, Gilles Romieu, et al.
NPJ Breast Cancer
|
June 27, 2017
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort
Xavier Pivot, Gilles Romieu, Pierre Fumoleau, et al.
Breast Cancer Research : BCR
|
August 24, 2017
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
Elsa Curtit, Xavier Pivot, Julie Henriques, et al.
Nature Communications
|
July 14, 2016
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
Anthony Ferrari, Anne Vincent-Salomon, Xavier Pivot, et al.
Page
of 9
Search research articles
Search
Showing results (71-80 of 81) with videos related to
Sort By:
Page
of 9
European Journal of Cancer (Oxford, England : 1990)
|
August 30, 2016
The challenge of rapid diagnosis in oncology: Diagnostic accuracy and cost analysis of a large-scale one-stop breast clinic
Suzette Delaloge, Julia Bonastre, Isabelle Borget, et al.
Annales De Pathologie
|
July 2, 2019
[GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting]
Aurélie Maran-Gonzalez, Camille Franchet, Raphaëlle Duprez-Paumier, et al.
BMC Cancer
|
July 24, 2013
SISH/CISH or qPCR as alternative techniques to FISH for determination of HER2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases
Jocelyne Jacquemier, Frédérique Spyratos, Benjamin Esterni, et al.
Annales De Pathologie
|
August 16, 2021
[2021 update of the GEFPICS' recommendations for HER2 status assessment in invasive breast cancer in France]
Camille Franchet, Lounes Djerroudi, Aurélie Maran-Gonzalez, et al.
Annales De Pathologie
|
December 3, 2014
[Pre-analytical stage for biomarker assessment in breast cancer: 2014 update of the GEFPICS' guidelines in France]
Gaëtan MacGrogan, Marie-Christine Mathieu, Bruno Poulet, et al.
Annales De Pathologie
|
December 3, 2014
[2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]
Frédérique Penault-Llorca, Anne Vincent-Salomon, Gaëtan MacGrogan, et al.
Oncotarget
|
October 21, 2016
GWAS in the SIGNAL/PHARE clinical cohort restricts the association between the FGFR2 locus and estrogen receptor status to HER2-negative breast cancer patients
David G Cox, Elsa Curtit, Gilles Romieu, et al.
NPJ Breast Cancer
|
June 27, 2017
Constitutional variants are not associated with HER2-positive breast cancer: results from the SIGNAL/PHARE clinical cohort
Xavier Pivot, Gilles Romieu, Pierre Fumoleau, et al.
Breast Cancer Research : BCR
|
August 24, 2017
Assessment of the prognostic role of a 94-single nucleotide polymorphisms risk score in early breast cancer in the SIGNAL/PHARE prospective cohort: no correlation with clinico-pathological characteristics and outcomes
Elsa Curtit, Xavier Pivot, Julie Henriques, et al.
Nature Communications
|
July 14, 2016
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers
Anthony Ferrari, Anne Vincent-Salomon, Xavier Pivot, et al.
Page
of 9